137 related articles for article (PubMed ID: 17141985)
21. Extended release amoxicillin/clavulanate: optimizing a product for respiratory infections based on pharmacodynamic principles.
Jacobs MR
Expert Rev Anti Infect Ther; 2005 Jun; 3(3):353-60. PubMed ID: 15954852
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients.
Carlier M; Noë M; De Waele JJ; Stove V; Verstraete AG; Lipman J; Roberts JA
J Antimicrob Chemother; 2013 Nov; 68(11):2600-8. PubMed ID: 23800901
[TBL] [Abstract][Full Text] [Related]
23. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate.
Kaye CM; Allen A; Perry S; McDonagh M; Davy M; Storm K; Bird N; Dewit O
Clin Ther; 2001 Apr; 23(4):578-84. PubMed ID: 11354391
[TBL] [Abstract][Full Text] [Related]
24. New formulations of amoxicillin/clavulanic acid: a pharmacokinetic and pharmacodynamic review.
Sánchez Navarro A
Clin Pharmacokinet; 2005; 44(11):1097-115. PubMed ID: 16231964
[TBL] [Abstract][Full Text] [Related]
25. [Pharmacokinetics/pharmacodynamics of the 1000/62.5 formulation of amoxicillin/clavulanic acid in odontostomatology].
Isla A; Canut A; Rodríguez Gascón A; Pedraz JL
Enferm Infecc Microbiol Clin; 2005; 23(6):387. PubMed ID: 15970176
[No Abstract] [Full Text] [Related]
26. [Sinusal penetration of amoxicillin-clavulanic acid. Formulation 1 g./125 mg., twice daily versus formulation 500 mg./125 mg., three times daily].
Jehl F; Klossek JM; Peynegre R; Serrano E; Castillo L; Bobin S; Desprez D; Renault C; Neel V; Rouffiac E; Borie C
Presse Med; 2002 Oct; 31(34):1596-603. PubMed ID: 12426976
[TBL] [Abstract][Full Text] [Related]
27. Comparative pharmacokinetics study of two different clindamycin capsule formulations: a randomized, two-period, two-sequence, two-way crossover clinical trial in healthy volunteers.
Sanki UK; Mandal BK; Chandrakala V
Arzneimittelforschung; 2011; 61(9):538-43. PubMed ID: 22029232
[TBL] [Abstract][Full Text] [Related]
28. Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection.
Rossi B; Soubirou JF; Chau F; Massias L; Dion S; Lepeule R; Fantin B; Lefort A
Antimicrob Agents Chemother; 2016 Jan; 60(1):424-30. PubMed ID: 26525800
[TBL] [Abstract][Full Text] [Related]
29. Bioequivalence of clavulanate potassium and amoxicillin (1:7) dispersible tablets in healthy volunteers.
Hu G; Dai Z; Long L; Han Y; Hou S; Wu L
J Huazhong Univ Sci Technolog Med Sci; 2002; 22(3):224-7. PubMed ID: 12658810
[TBL] [Abstract][Full Text] [Related]
30. Disposition and oral bioavailability of amoxicillin and clavulanic acid in pigs.
Reyns T; De Boever S; Baert K; Croubels S; Schauvliege S; Gasthuys F; De Backer P
J Vet Pharmacol Ther; 2007 Dec; 30(6):550-5. PubMed ID: 17991223
[TBL] [Abstract][Full Text] [Related]
31. Bioequivalence evaluation of two brands of amoxicillin/clavulanic acid 250/125 mg combination tablets in healthy human volunteers: use of replicate design approach.
Idkaidek NM; Al-Ghazawi A; Najib NM
Biopharm Drug Dispos; 2004 Dec; 25(9):367-72. PubMed ID: 15495146
[TBL] [Abstract][Full Text] [Related]
32. Highly variable absorption of clavulanic acid during the day: a population pharmacokinetic analysis.
De Velde F; De Winter BCM; Koch BCP; Van Gelder T; Mouton JW;
J Antimicrob Chemother; 2018 Feb; 73(2):469-476. PubMed ID: 29136160
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic studies of amoxicillin, potassium clavulanate and their combination.
Witkowski G; Lode H; Höffken G; Koeppe P
Eur J Clin Microbiol; 1982 Aug; 1(4):233-7. PubMed ID: 7173186
[TBL] [Abstract][Full Text] [Related]
34. Comparative bioavailability and pharmacokinetic study of Cefadroxil capsules in male healthy volunteers of Pakistan.
Rahim N; Naqvi SB; Alam M; Rasheed A; Khalique UA
Pak J Pharm Sci; 2016 Mar; 29(2):453-9. PubMed ID: 27087092
[TBL] [Abstract][Full Text] [Related]
35. The stability of amoxicillin trihydrate and potassium clavulanate combination in aqueous solutions.
Jerzsele A; Nagy G
Acta Vet Hung; 2009 Dec; 57(4):485-93. PubMed ID: 19897453
[TBL] [Abstract][Full Text] [Related]
36. [Predictive pharmacodynamic criteria and efficacy of augmentin 1 g/125 mg in 2 doses per day].
Jehl F
Presse Med; 2000 Sep; 29(26 Suppl):9-10. PubMed ID: 11045112
[No Abstract] [Full Text] [Related]
37. A Three-Pulse Release Tablet for Amoxicillin: Preparation, Pharmacokinetic Study and Physiologically Based Pharmacokinetic Modeling.
Li J; Chai H; Li Y; Chai X; Zhao Y; Zhao Y; Tao T; Xiang X
PLoS One; 2016; 11(8):e0160260. PubMed ID: 27479702
[TBL] [Abstract][Full Text] [Related]
38. Cyclodextrin multicomponent complexation and controlled release delivery strategies to optimize the oral bioavailability of vinpocetine.
Ribeiro LS; Falcão AC; Patrício JA; Ferreira DC; Veiga FJ
J Pharm Sci; 2007 Aug; 96(8):2018-28. PubMed ID: 17530626
[TBL] [Abstract][Full Text] [Related]
39. Floating-bioadhesive gastroretentive Caesalpinia pulcherrima-based beads of amoxicillin trihydrate for Helicobacter pylori eradication.
Thombre NA; Gide PS
Drug Deliv; 2016; 23(2):405-19. PubMed ID: 24870198
[TBL] [Abstract][Full Text] [Related]
40. Comparative pharmacokinetics of two tablet formulations of amoxicillin: bioequivalence assessment.
Sailer R; Arnold P; Erenmemişoğlu A; Martin W; Tamur U; Kanzik I; Hincal AA
Arzneimittelforschung; 2007; 57(4):227-31. PubMed ID: 17515293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
